share_log
Breakings ·  May 30 19:30
Patient Dosing Commenced in Reposa Phase 2/3 Clinical Trial Protocol to Assess Ihl-42X Drug in Patients With Obstructive Sleep Apnea
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment